"I don't have a crystal ball, but my guess is from our survey that the folks using the oral version of the drug will be a new set of people, because one of the barriers to trial was as can be expected a lot of people don't like to take shots of injections," Johnson said
This fills in the nutritional gaps
While the cost of GLP-1 coverage is top of mind for employers right now, they should not forget to factor in the significant cost of obesity-related complications, said Elina Onitskansky, the founder and CEO of obesity treatment company Ilant Health
When combined, the appetite-suppressing effect of Ozempic dominates
(2023) Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in type 2 diabetes N Engl J Med 389(6):503-513
Already got green light for 4 peptides ,3 more to come but this is just a crossing 1st hurdle and lot more to do Day 1 - still going on, 4pm Pacific time